ObGyn.net is looking for US-based MDs to share their thoughts on new clinical developments, practice management issues, patient conundrums, regulatory headaches, and more.
ObGyn.net is looking for US-based MDs to share their thoughts on new clinical developments, practice management issues, patient conundrums, regulatory headaches, and more. The content should be directed at physicians, and should have a perspective; we want more than just a rehashing of clinical research, we want you to share your experiences and opinions!
Bloggers are paid, and can contribute weekly, biweekly or monthly. Posts should be between 300-600 words.
Interested? Email us at obgyn@ubm.com.
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More